Drugs / Fecal Microbiota Transplant
Fecal Microbiota Transplant
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02390726 | Dec 2015 → Dec 2017 | ulcerative colitis | University of Vermont | Unknown | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT05967871 | Mar 2024 → Dec 2026 expected | small intestinal bacterial overgrowth | McMaster Children's Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04139577 | Jun 2021 → Aug 2022 | acute graft versus host disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03998423 | Nov 2019 → Jul 2020 | Alzheimer disease | University of Wisconsin, Madison | Terminated | No outcome recorded |
| Phase 1 | NCT02636517 | Dec 2015 → Dec 2027 expected | Clostridium difficile colitis, Crohn disease, ulcerative colitis | Judith Kelsen | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT01947101 | Feb → Dec 2014 | ulcerative colitis | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01914731 | Aug 2013 → Oct 2014 | Clostridium difficile colitis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02330653 | Nov 2015 → Apr 2019 | Crohn disease, ulcerative colitis | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02199561 | Jul 2014 → Dec 2016 | Crohn disease | University of Alberta | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03420482 | Apr 2018 → Dec 2026 expected | hepatic encephalopathy | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03408886 | Jan 2018 → Apr 2022 overdue | autism spectrum disorder, digestive system disorder | Arizona State University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03110133 | May 2017 → Feb 2020 | Clostridium difficile colitis | Finch Research and Development LLC. | Completed | No outcome recorded |
| Phase 2 | NCT03078803 | Mar 2017 → Jun 2021 | Crohn disease | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT02394275 | Mar 2014 → Sep 2016 | Clostridium difficile colitis | McMaster University | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02254811 | Sep 2014 → Dec 2016 | Clostridium difficile colitis | University of Alberta | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02968511 | Sep 2016 → Nov 2017 | Clostridium difficile colitis | Milton S. Hershey Medical Center | Withdrawn | No outcome recorded |
| — | NCT02721264 | Mar 2016 → Jun 2018 | metabolic dysfunction-associated steatohepatitis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02343328 Comparator | Jan 2015 → Jul 2016 | Clostridium difficile colitis | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06593366 Comparator | Jun 2026 → Jun 2027 expected | anorexia nervosa | Hamilton Health Sciences Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fecal Microbiota Transplant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01914731 ↗ |
| Known as | Fecal Microbiota Transplantation | “Fecal Microbiota Transplantation (FMT)” NCT02721264 ↗ |
| Known as | FMT | “The purpose of this pilot randomized-controlled trial is to determine whether Fecal Microbiota Transplant (FMT) treatment demonstrates feasibility, acceptability, and prelinary...” NCT06593366 ↗4“The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) for treating patients with mild to moderate Ulcerative Colitis (UC).” NCT02390726 ↗ “The investigators wish to compare Fecal Microbiota Transplant (FMT) capsules to placebo capsules in subjects with TWO episodes of C. difficile.” NCT02343328 ↗ “fecal microbiota transplant (FMT) may treat hepatic encephalopathy (HE)” PMID 35384391 ↗ Apr 2022 “Fecal Microbiota Transplantation (FMT)” NCT02721264 ↗ |
| Known as | FSM | “followed by oral administration of Full Spectrum Microbiota (FSM) or placebo.” NCT03408886 ↗ |
| Known as | Full Spectrum Microbiota | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110133 ↗ |
| Action | Restore | “transfer of healthy human gut bacteria to restore the microbiome” NCT02254811 ↗ |
| Modality | Other / unclassified | “The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations” NCT02330653 ↗ |
| Route | Oral | “inoculum administered by frozen orally-administered capsules” NCT01914731 ↗ |